# Gal Markel

Source: https://onco.cc/people/gal-markel/  
OnCo record `gal-markel` (Person). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A tumour immunologist who helped build Israel's melanoma cell therapy programme at Sheba and now runs the melanoma centre at Davidoff, publishing what checkpoint drugs do outside the clean conditions of a trial.

## Summary

Gal Markel was part of the group at Sheba's Ella Lemelbaum Institute that established tumour-infiltrating lymphocyte therapy in Israel, and now directs the Skin Cancer and Melanoma Center at the Davidoff Cancer Center, Rabin Medical Center, with an appointment in clinical microbiology and immunology at Tel Aviv University. His recent published work is largely real-world: outcomes of dual checkpoint blockade with nivolumab and ipilimumab outside trial populations, PD-1 inhibitors in cutaneous squamous cell carcinoma in organ transplant recipients, and body-composition measurements from routine computed tomography as a predictor of survival on immunotherapy. He was also an investigator on the adjuvant vibostolimab and pembrolizumab melanoma trial.

## Fields

- Kind: Person
- Last checked: 2026-09-25
- Tags: clinician-scientist; immunotherapy
- Role: Director, Skin Cancer and Melanoma Center, Davidoff Cancer Center, Rabin Medical Center; Gray Faculty of Medical and Health Sciences, Tel Aviv University
- Specialisms: Melanoma; Tumour immunology; Checkpoint inhibitors; Real-world outcomes

## Sources

- Davidoff Cancer Center, Rabin Medical Center: https://hospitals.clalit.co.il/rabin
- PubMed author search: https://pubmed.ncbi.nlm.nih.gov/?term=Markel%20G%5BAuthor%5D%20melanoma

## Connected records

- cancers: [Melanoma](https://onco.cc/cancers/melanoma/)
- fronts: [Immunotherapy](https://onco.cc/fronts/immunotherapy/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/), [TIL therapy](https://onco.cc/technologies/til-therapy/)
- institutions: [Davidoff Cancer Center, Rabin Medical Center](https://onco.cc/institutions/rabin-davidoff-center/), [Sheba Medical Center](https://onco.cc/institutions/sheba/), [Tel Aviv University](https://onco.cc/institutions/tel-aviv-university/)
- key papers: [Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies](https://onco.cc/key-papers/paper-besser-til-melanoma-intent-to-treat-ccr-2013/)

---
JSON: https://onco.cc/api/v1/entities/gal-markel.json